Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.

ABSTRACT:

Objective

To evaluate the cost-utility of different treatment strategies in severe RA after TNF-inhibitor failure.

Methods

The cost-effectiveness of treatment strategies was compared in a group of hypothetical Finnish RA patients. Initially, the patients received either best supportive care (BSC) or one of the following treatments before BSC: adalimumab (ADAL), abatacept (ABAT), etanercept (ETAN), infliximab (INFL) or rituximab (RTX). Further treatments were added to the most cost-effective strategy in a stepwise manner. The analysis was performed on an Excel-based Markov state transition model using the probabilistic approach. The clinical outcomes related to treatments were estimated from published clinical trials. The gained quality-adjusted life-years (QALYs) were estima

SUBMITTER: Hallinen TA 

PROVIDER: S-EPMC2838414 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature